K V PHARMA CL A (GREY:KVPHQ)

K-V Pharmaceutical Company operates as a specialty branded pharmaceutical marketing company primarily focusing on women’s health care in the United States. It provides Evamist, a transdermal estrogen therapy, which delivers a low dose of estradiol for the treatment of moderate-to-severe vasomotor symptoms due to menopause; and Makena, a hydroxyprogesterone caproate injection, which reduces the risk of preterm birth in women with a singleton pregnancy, who have a history of singleton spontaneous preterm birth. The company markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and indirectly to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, and government entities principally through wholesaler or distributor customers. K-V Pharmaceutical Company was founded in 1942 and is headquartered in St. Louis, Missouri. On August 4, 2012, K-V Pharmaceutical Company filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York, Manhattan. It is in joint administration with K-V Discovery Solutions, Inc.